Sphenopalatine Ganglion Stimulation


Improves Outcome from Acute Ischemic Stroke in a Dose-Dependent Manner:

Further Insights from the Pivotal ImpACT-24B Trial



JL Saver, NM Bornstein, H-C Diener, PB Gorelick, T Janelidze, M Savic, N Zarqua, A Shuaib, D Yarnitsky, CA Molina for the ImpACT-24B Trial Investigators

ImpACT-24B Pivotal Trial






Stimulation



Implantation





	Study Design
Objective	Safety & efficacy in anterior circulation stroke started 8-24h after onset
Design	Randomized, Double-Blind, Sham-Controlled
Primary Endpoint	mRS improvement beyond expectations at 3 months (sliding dichotomy)
Two Primary Analysis Populations	 mITT – all patients receiving at least one active/sham SPG stimulation Confirmed Cortical Involvement (CCI) - NIHSS ≥ 10, at least one cortical ASPECTS region

Efficacy Results


mITT	SPG Stimulation	Sham Control	Odds Ratio	Odds Ratio		P Value
Sliding Dichotomy	48.6%	45·5%	1.14 [0.89, 1.46]	I		0.31
Dichotomy 0-2	44.1%	41.8%	1.10 [0.85, 1.41]	F		0.47
Dichotomy 0-3	67.6%	63·0%	1.22 [0.94, 1.59]		⊢− −−1	0.13
SIS-16	57.7	54.7	1.15 [0.92, 1.44]		⊢− −−1	0.23
Utility weighted mRS	55.83	53·18	1.13 [0.90, 1.41]		⊢ _ ●i	0.24
				0.40	1.00	2.50
				Favors Sham Control	Favors SPG Stimu	ulation
	600					

ССІ	SPG Stimulation	Sham Control	Odds Ratio	Odds	Ratio	P Value
Sliding Dichotomy	49.6%	39.9%	1.48 [1.05, 2.10]		├─── ↓	0.0258
Dichotomy 0-2	34.8%	27.2%	1.43 [0.99, 2.08]		•i	0.06
Dichotomy 0-3	62.3%	51.1%	1·58 [1·11, 2·25]		• 	0.01
SIS-16	52.2	43·9	1.48 [1.08, 2.02]		⊢	0.01
Utility weighted mRS	50.00	43.89	1·37 [1·00, 1·87]			0.05
				0.40 1	·00 2·5	50

Favors Sham Control

Favors SPG Stimulation

Relation Between Stimulation Level and Clinical Outcomes




Inverted U-Shaped Dose Effect Curve (IUSDEC)

Endpoint	CCI	Non-CCI
Favorable Outcome (mRS Sliding Dichotomy)	0.003	0.54
Independence (mRS 0-2)	0.02	0.67
Self-Care or Better (mRS 0-3)	0.01	0.88
Stroke-Related QOL (SIS-16)	0.02	0.67
Disability level (UW-mRS)	0.03	0.95

*Adjusted for: age, sex, NIHSS, side, ASPECTS, OTT, DM, AF. and predicted mRS mean-median difference

Outcome	SPG stim (N=61)	Sham stim (N=276)	Odds ratio (95% CI)	p-value
Favorable Outcome (mRS Sliding Dichotomy)	68.9%	39.9%	3.34 (1.84-6.04)	<0.0001
Independence (mRS 0-2)	54.1%	27.2%	3.16 (1.79-5.58)	<0.0001
Self-Care or Better (mRS 0-3)	82.0%	51.1%	4·35 (2·17-8·71)	<0.0001
	SPG stim (N=61)	Sham stim (N=276)	Diff. (95% CI)	p-value
Stroke-Related QoL (SIS-16)	67.3	43.9	23.5 (12.7-34.2)	<0.0001
Disability level (UW-mRS)	64.6	43.9	20.7 (10.8-30.6)	<0.0001

Clinical Dose-Response in 24B Trial Matches Physiologic Dose-Resp in Later 24M Trial*



*ImpACT-24M presented at ISC 2019

6

Discussion

- SPG stimulation was safe in all patients and showed evidence of benefit in patients with confirmed cortical involvement up to 24h from onset. Results further supported by:
 - Consistent beneficial effects on all secondary efficacy endpoints
 - Similar findings in preceding pilot ImpACT-24A trial
 - Increased and robust statistical significance in individual-patient-data pooled meta-analysis
 - <u>Strong dose-response relationship, with inverted U-shaped dose-effect curve (IUSDEC)</u>
- ImpACT-24B benefit magnitude for every 100 patients treated with SPG stimulation:
 - 10 more will have a favorable long-term disability outcome
 - At optimal stimulation levels, potentially 29 more will have a favorable long-term disability outcome

"The cumulative evidence indicates that sphenopalatine ganglion stimulation is an efficacious therapy for patients with cortical acute ischaemic stroke 8–24 hours after onset who are ineligible for intravenous thrombolytic therapy."

--Lancet May 24, 2019, online ahead of print